Authors: Patricia Diez1, Chloe Brooks1, Alison Tree2,3, Matthew Hatton4, Anoop Haridass5, Nicholas van As2,6, Emma M Dunne7, John Conibear8, Katharine Aitken9,2, Rebecca Muirhead10, Clive Peedell11, Fiona McDonald12
1National Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, Radiotherapy Physics, Northwood, United Kingdom; 2Institute of Cancer Research, Division of Radiotherapy and Imaging, Sutton, United Kingdom; 3The Royal Marsden NHS Foundation Trust, Urology Unit, Sutton, United Kingdom; 4Weston Park Hospital, Department of Clinical Oncology, Sheffield, United Kingdom; 5Clatterbridge Cancer Centre, Department of Clinical Oncology, Liverpool, United Kingdom; 6The Royal Marsden NHS Foundation Trust, Urology Unit, London, United Kingdom; 7BC Cancer - Vancouver Centre, Department of Radiation Oncology, Vancouver, Canada; 8Barts Cancer Centre, Radiotherapy Department, London, United Kingdom; 9The Royal Marsden NHS Foundation Trust, GI Unit, Sutton, United Kingdom; 10Oxford University Hospitals Foundation Trust, Department of Oncology, Oxford, United Kingdom; 11South Tees NHS Foundation Trust, Department of Clinical Oncology, Middlesbrough, United Kingdom; 12The Royal Marsden NHS Foundation Trust, Lung Unit, London, United Kingdom